Traeger, INC. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share COOK The New York Stock Excha
• $1.00 — he Company's common stock was less than $1.00 per share over a consecutive 30 trading

Filing Documents

• tra-20251119.htm (8-K) — 41KB
• q3-25pressreleasexnysenoti.htm (EX-99.1) — 10KB
• image.jpg (GRAPHIC) — 76KB
• 0001628280-25-053796.txt ( ) — 278KB
• tra-20251119.xsd (EX-101.SCH) — 2KB
• tra-20251119_lab.xml (EX-101.LAB) — 22KB
• tra-20251119_pre.xml (EX-101.PRE) — 13KB
• tra-20251119_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On Novembe r 19, 2025 , Traeger, Inc. (the "Company") received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") that it is not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE's Listed Company Manual ("Section 802.01C") because the average closing price of the Company's common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 14, 2025. The Notice does not result in the immediate delisting of the Company's common stock from the NYSE. The Company intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE's continued listing standards, including a reverse stock split, subject to approval by the Company's Board of Directors and stockholders. In accordance with applicable NYSE rules, the Company can regain compliance at any time within a six-month cure period following its receipt of the Notice if, on the last trading day of any calendar month during such cure period (or the last trading day of the cure period), the Company has both: (i) a closing price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of the applicable calendar month or the cure period. Under the NYSE's rules, if the Company determines that it will cure the stock price deficiency by taking an action requiring shareholder approval at its next annual meeting, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the next 30 trading days. The Notice has no immediate impact on the listing of the Company's common stock, which will remain listed and traded on the NYSE during the six-month cure period, subject to the Company's compliance with the other continued

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. As required by Section 802.01C, the Company issued a press release on November 24, 2025, announcing its receipt of the Notice. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under the Section and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's plans with respect to the NYSE notice of non-compliance, including a potential reverse stock split. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: reactions from our employees, vendors, customers, lenders and investors to the Company's receipt of the NYSE notice of non-compliance, the Company's ability to regain compliance with the minimum share price requirement within the applicable cure period; the Company's ability to comply with other NYSE listing standards and maintain the listing of its common stock on the NYSE; the impact of management transitions on our common stock; our ability to manage our future growth effectively; our ability to expand into additional markets; our ability to maintain and strengthen our brand to generate and maintain ongoing demand for our products; our ability to cost-effectively attract new customers and retain our existing customers; the highly competitive market in which we operate; and the ability of our st

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 24 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Traeger, Inc. Date: November 24, 2025 By: /s/ Michael J. Hord Michael J. Hord Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR